Literature DB >> 12377803

Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria.

N Borruel1, M Carol, F Casellas, M Antolín, F de Lara, E Espín, J Naval, F Guarner, J R Malagelada.   

Abstract

BACKGROUND AND AIMS: Tumour necrosis factor alpha (TNF-alpha) plays a key role in the pathogenesis of intestinal inflammation in Crohn's disease. The effect of bacteria on TNF-alpha release by intestinal mucosa was investigated.
METHODS: Ileal specimens were obtained at surgery from 10 patients with Crohn's disease (ileal stricture) and five disease controls undergoing right hemicolectomy (caecal cancer). Mucosal explants from each specimen were cultured for 24 hours with either non-pathogenic Escherichia coli, Lactobacillus casei DN-114001, L bulgaricus LB10, or L crispatus (each study contained blank wells with no bacteria). Tissue and bacterial viability was confirmed by lactate dehydrogenase (LDH) release and culture. Concentrations of TNF-alpha were measured in supernatants and the phenotype of the intestinal lymphocytes was analysed by flow cytometry.
RESULTS: Coculture of mucosa with bacteria did not modify LDH release. Release of TNF-alpha by inflamed Crohn's disease mucosa was significantly reduced by coculture with L casei or L bulgaricus; changes induced by L crispatus or E coli were not significant. The effect of L casei and L bulgaricus was not prevented by protease inhibitors. Coculture with L casei and L bulgaricus reduced the number of CD4 cells as well as TNF-alpha expression among intraepithelial lymphocytes from Crohn's disease mucosa. None of the bacteria induced changes in non-inflamed mucosa.
CONCLUSIONS: Probiotics interact with immunocompetent cells using the mucosal interface and modulate locally the production of proinflammatory cytokines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12377803      PMCID: PMC1773447          DOI: 10.1136/gut.51.5.659

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  43 in total

1.  Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance.

Authors:  K Ina; J Itoh; K Fukushima; K Kusugami; T Yamaguchi; K Kyokane; A Imada; D G Binion; A Musso; G A West; G M Dobrea; T S McCormick; E G Lapetina; A D Levine; C A Ottaway; C Fiocchi
Journal:  J Immunol       Date:  1999-07-15       Impact factor: 5.422

2.  Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice.

Authors:  K L Madsen; J S Doyle; L D Jewell; M M Tavernini; R N Fedorak
Journal:  Gastroenterology       Date:  1999-05       Impact factor: 22.682

3.  Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial.

Authors:  G D'haens; S Van Deventer; R Van Hogezand; D Chalmers; C Kothe; F Baert; T Braakman; T Schaible; K Geboes; P Rutgeerts
Journal:  Gastroenterology       Date:  1999-05       Impact factor: 22.682

4.  Ex vivo effects of lactobacilli, streptococci, and bifidobacteria ingestion on cytokine and nitric oxide production in a murine model.

Authors:  M V Tejada-Simon; Z Ustunol; J J Pestka
Journal:  J Food Prot       Date:  1999-02       Impact factor: 2.077

5.  Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

Authors:  P Rutgeerts; G D'Haens; S Targan; E Vasiliauskas; S B Hanauer; D H Present; L Mayer; R A Van Hogezand; T Braakman; K L DeWoody; T F Schaible; S J Van Deventer
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

6.  Mucosal cytokine expression, cellular markers and adhesion molecules in inflammatory bowel disease.

Authors:  A Woywodt; D Ludwig; P Neustock; A Kruse; K Schwarting; G Jantschek; H Kirchner; E F Stange
Journal:  Eur J Gastroenterol Hepatol       Date:  1999-03       Impact factor: 2.566

7.  Stimulation of transforming growth factor beta1 by enteric bacteria in the pathogenesis of rat intestinal fibrosis.

Authors:  M Mourelle; A Salas; F Guarner; E Crespo; A García-Lafuente; J R Malagelada
Journal:  Gastroenterology       Date:  1998-03       Impact factor: 22.682

8.  Milk fermented with yogurt cultures and Lactobacillus casei compared with yogurt and gelled milk: influence on intestinal microflora in healthy infants.

Authors:  C Guerin-Danan; C Chabanet; C Pedone; F Popot; P Vaissade; C Bouley; O Szylit; C Andrieux
Journal:  Am J Clin Nutr       Date:  1998-01       Impact factor: 7.045

9.  Successful management of Crohn's disease of the ileoanal pouch with infliximab.

Authors:  E Ricart; R Panaccione; E V Loftus; W J Tremaine; W J Sandborn
Journal:  Gastroenterology       Date:  1999-08       Impact factor: 22.682

10.  Stimulation of cytokine production in clonal macrophage and T-cell models by Streptococcus thermophilus: comparison with Bifidobacterium sp. and Lactobacillus bulgaricus.

Authors:  M L Marin; M V Tejada-Simon; J H Lee; J Murtha; Z Ustunol; J J Pestka
Journal:  J Food Prot       Date:  1998-07       Impact factor: 2.077

View more
  83 in total

1.  Lactobacillus paracasei and Lactobacillus plantarum strains downregulate proinflammatory genes in an ex vivo system of cultured human colonic mucosa.

Authors:  Christine Bäuerl; Marta Llopis; María Antolín; Vicente Monedero; Manuel Mata; Manuel Zúñiga; Francisco Guarner; Gaspar Pérez Martínez
Journal:  Genes Nutr       Date:  2012-06-06       Impact factor: 5.523

2.  Role of interleukin (IL-10) in probiotic-mediated immune modulation: an assessment in wild-type and IL-10 knock-out mice.

Authors:  B Sheil; J MacSharry; L O'Callaghan; A O'Riordan; A Waters; J Morgan; J K Collins; L O'Mahony; F Shanahan
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

Review 3.  Probiotics in inflammatory bowel disease: is it all gut flora modulation?

Authors:  S Ghosh; D van Heel; R J Playford
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

4.  Mucosal and cellular immune responses elicited by recombinant Lactococcus lactis strains expressing tetanus toxin fragment C.

Authors:  K Robinson; L M Chamberlain; M C Lopez; C M Rush; H Marcotte; R W F Le Page; J M Wells
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

5.  Anti-inflammatory and immunomodulatory efficacy of indigenous probiotic Lactobacillus plantarum Lp91 in colitis mouse model.

Authors:  Raj Kumar Duary; Mache Amit Bhausaheb; Virender Kumar Batish; Sunita Grover
Journal:  Mol Biol Rep       Date:  2011-09-23       Impact factor: 2.316

6.  Use of probiotics in gastrointestinal disorders: what to recommend?

Authors:  Elizabeth C Verna; Susan Lucak
Journal:  Therap Adv Gastroenterol       Date:  2010-09       Impact factor: 4.409

7.  Differential activities of four Lactobacillus casei promoters during bacterial transit through the gastrointestinal tracts of human-microbiota-associated mice.

Authors:  R Oozeer; J P Furet; N Goupil-Feuillerat; J Anba; J Mengaud; G Corthier
Journal:  Appl Environ Microbiol       Date:  2005-03       Impact factor: 4.792

Review 8.  Probiotics in the management of colonic disorders.

Authors:  Eamonn M M Quigley
Journal:  Curr Gastroenterol Rep       Date:  2007-10

9.  Initiation of protein synthesis by a labeled derivative of the Lactobacillus casei DN-114 001 strain during transit from the stomach to the cecum in mice harboring human microbiota.

Authors:  R Oozeer; D D G Mater; N Goupil-Feuillerat; G Corthier
Journal:  Appl Environ Microbiol       Date:  2004-12       Impact factor: 4.792

10.  Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis.

Authors:  B Sheil; J McCarthy; L O'Mahony; M W Bennett; P Ryan; J J Fitzgibbon; B Kiely; J K Collins; F Shanahan
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.